Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, have entered into a definitive agreement under which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.   The acquisition adds MiroBio’s discovery platform and portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective ...